title: Antigen incorporated in virus-like particles is delivered to specific dendritic cell subsets that induce an effective antitumor immune response in vivo.
abstract: Virus-like particles (VLP) from rabbit hemorrhagic disease virus (RHDV) can be used as a scaffold to facilitate the delivery of antigens to induce cell-mediated immune responses. In this study, we investigated the immune response to lymphocytic choriomeningitis virus-derived peptide antigen (gp33) delivered by RHDV VLP. The gp33 peptides were incorporated into the VLP in 2 different forms, either recombinantly expressed inside the VLP (VLP-gp33r) or chemically coupled to the surface of the VLP (VLP-gp33c). We showed that VLP-gp33r induced a greater level of cytotoxicity than VLP-gp33c against gp33-coated target cells in vivo. Both VLP, when delivered as prophylactic vaccines, inhibited the growth of Lewis' lung carcinoma tumors expressing gp33 (LL-LCMV) in mice to a similar degree. Studies to investigate the mechanism induced by these VLP showed that 2 CD11c DC subsets, CD8α and CD8α, acquired VLP in vivo and in vitro, and VLP-gp33r were cross-presented by both these subsets to prime CD8 T cells through a TAP-independent, endosomal recycling pathway. Depletion of Langerin DC in vivo before and after vaccination with VLP-gp33r, lead to reduced cytotoxicity implicating these cells in the induction of cytotoxic effector cells. These results suggest that recombinant VLP expressing tumor peptides targeted to Langerin DC may have clinical application. Finally we found that VLP-gp33r were more effective antitumor vaccines than VLP-gp33c when delivered therapeutically. The findings of this study suggest the potential of VLP as a platform for delivery of tumor-associate antigen and elicit protective immunity against tumors.
authors.affiliation: Department of Pathology, University of Otago, Dunedin, New Zealand.
authors.forename: Kunyu
authors.initials: K
authors.lastname: Li
authors.forename: Amanda
authors.initials: A
authors.lastname: Peers-Adams
authors.forename: Stephanie J
authors.initials: SJ
authors.lastname: Win
authors.forename: Sarah
authors.initials: S
authors.lastname: Scullion
authors.forename: Michelle
authors.initials: M
authors.lastname: Wilson
authors.forename: Vivienne L
authors.initials: VL
authors.lastname: Young
authors.forename: Paula
authors.initials: P
authors.lastname: Jennings
authors.forename: Vernon K
authors.initials: VK
authors.lastname: Ward
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Baird
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Young
mesh_terms: D000818:Animals; D000956:Antigens, Viral / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage*; D018827:Carcinoma, Lewis Lung / Q000276:immunology / Q000628:therapy*; D045744:Cell Line, Tumor; D002470:Cell Survival; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D017929:Hemorrhagic Disease Virus, Rabbit / Q000276:immunology*; D008217:Lymphocytic choriomeningitis virus / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D010455:Peptides / Q000276:immunology
chemical_list: D000956:Antigens, Viral; D019496:Cancer Vaccines; D010455:Peptides